Buckingham Strategic Partners Cuts Stock Position in Merck & Co., Inc. (NYSE:MRK)

Buckingham Strategic Partners cut its holdings in Merck & Co., Inc. (NYSE:MRKGet Rating) by 30.4% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,826 shares of the company’s stock after selling 2,109 shares during the quarter. Buckingham Strategic Partners’ holdings in Merck & Co., Inc. were worth $395,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Financial Avengers Inc. lifted its position in Merck & Co., Inc. by 115.8% in the 4th quarter. Financial Avengers Inc. now owns 328 shares of the company’s stock valued at $25,000 after acquiring an additional 176 shares in the last quarter. Joseph P. Lucia & Associates LLC bought a new position in shares of Merck & Co., Inc. during the 1st quarter valued at $25,000. Landmark Wealth Management LLC bought a new position in shares of Merck & Co., Inc. during the 1st quarter valued at $25,000. Front Row Advisors LLC lifted its holdings in shares of Merck & Co., Inc. by 89.4% during the 4th quarter. Front Row Advisors LLC now owns 339 shares of the company’s stock valued at $26,000 after buying an additional 160 shares during the period. Finally, Okabena Investment Services Inc. bought a new position in shares of Merck & Co., Inc. during the 4th quarter valued at $27,000. 72.88% of the stock is owned by institutional investors.

Merck & Co., Inc. Trading Down 0.0 %

Shares of Merck & Co., Inc. stock opened at $90.59 on Wednesday. The firm has a market cap of $229.49 billion, a price-to-earnings ratio of 13.87, a PEG ratio of 1.22 and a beta of 0.32. The business has a 50-day moving average price of $90.11 and a 200-day moving average price of $85.89. The company has a quick ratio of 1.15, a current ratio of 1.39 and a debt-to-equity ratio of 0.66. Merck & Co., Inc. has a twelve month low of $70.89 and a twelve month high of $95.72.

Merck & Co., Inc. (NYSE:MRKGet Rating) last issued its quarterly earnings data on Thursday, July 28th. The company reported $1.87 earnings per share for the quarter, beating analysts’ consensus estimates of $1.69 by $0.18. Merck & Co., Inc. had a return on equity of 48.45% and a net margin of 29.00%. The firm had revenue of $14.59 billion during the quarter, compared to analyst estimates of $13.85 billion. During the same quarter last year, the business posted $1.31 earnings per share. The business’s quarterly revenue was up 28.0% compared to the same quarter last year. Equities research analysts anticipate that Merck & Co., Inc. will post 7.31 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 7th. Investors of record on Thursday, September 15th will be issued a $0.69 dividend. This represents a $2.76 dividend on an annualized basis and a dividend yield of 3.05%. The ex-dividend date of this dividend is Wednesday, September 14th. Merck & Co., Inc.’s payout ratio is 42.27%.

Analyst Ratings Changes

Several research firms have recently weighed in on MRK. SVB Leerink reissued an “outperform” rating and set a $102.00 price target on shares of Merck & Co., Inc. in a report on Monday, June 6th. Daiwa Capital Markets raised Merck & Co., Inc. from a “neutral” rating to a “buy” rating and increased their price target for the company from $89.00 to $102.00 in a report on Wednesday, July 6th. Cowen increased their price target on Merck & Co., Inc. from $95.00 to $102.00 and gave the company a “market perform” rating in a report on Monday, June 27th. Morgan Stanley raised their target price on Merck & Co., Inc. from $88.00 to $92.00 and gave the stock an “equal weight” rating in a report on Friday, July 29th. Finally, Atlantic Securities raised their target price on Merck & Co., Inc. from $105.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, July 13th. Eight investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $97.44.

About Merck & Co., Inc.

(Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Read More

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.